Jonathan Ntale
A5061059188- HIV/AIDS Research and Interventions
- HIV, Drug Use, Sexual Risk
- HIV Research and Treatment
- HIV-related health complications and treatments
- COVID-19 epidemiological studies
- Global Maternal and Child Health
- HIV/AIDS drug development and treatment
Centers for Disease Control and Prevention
2021-2024
Center for Global Health
2023
One component of the Joint United Nations Programme on HIV/AIDS (UNAIDS) goal to end epidemic by 2030, is that 95% all persons receiving antiretroviral therapy (ART) achieve viral suppression.
On January 28, 2003, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), largest commitment by any nation to address a single disease in history, was announced.* In April 2004, first person world receive PEPFAR-supported antiretroviral therapy (ART) man aged 34 years Uganda. Effective ART reduces morbidity and mortality among persons with HIV infection (1) prevents both mother-to-child transmission (MTCT) (2) sexual once viral load is suppressed undetectable levels (<200 copies/mL)...
HIV-positive children and adolescents face gaps in viral load (VL) testing. To understand trends pediatric/adolescent VL testing, 7 countries collected data from Laboratory Information Management Systems. Results showed increasing proportion of tests done through dried blood spot (DBS) decreased sample rejection rates for DBS compared with plasma, supporting use when skilled phlebotomy is unavailable.
Background In 2019, WHO recommended dolutegravir (DTG) as a backbone for first- and second-line antiretroviral therapy (ART) regimens people living with HIV (PLHIV). According to the 2018 Uganda’s treatment guidelines, patients viral non-suppression (≥1,000 copies/mL) should receive intensive adherence counseling (IAC) repeat load (VL) within 6 months. This analysis focused on prevalence factors associated suppression following IAC among PLHIV DTG-based (DBRs) an initial episode of (VNS) in...